Bill Text: IN HB1315 | 2013 | Regular Session | Engrossed
Bill Title: Professional health services.
Spectrum: Bipartisan Bill
Status: (Passed) 2013-05-13 - Public Law 274 [HB1315 Detail]
Download: Indiana-2013-HB1315-Engrossed.html
Citations Affected: IC 16-18; IC 16-42; noncode.
Synopsis: Biosimilar biological products. Allows a pharmacist to
substitute an interchangeable biosimilar product for a prescribed
biological product if certain conditions are met. Requires the board of
pharmacy to maintain an Internet web site that lists the biosimilar
biological products that are determined to be interchangeable. Allows
the board of pharmacy to adopt rules. Provides that a written or
electronic prescription for a biological product must comply with the
existing prescription form requirements. Requires the health finance
commission to study, during the 2013 legislative interim, how Indiana
law should address the prescribing and substituting of biosimilar
biological products.
Effective: July 1, 2013.
(SENATE SPONSORS _ MILLER PATRICIA, GROOMS)
January 17, 2013, read first time and referred to Committee on Public Health.
January 29, 2013, amended, reported _ Do Pass.
January 31, 2013, read second time, amended, ordered engrossed.
February 1, 2013, engrossed.
February 4, 2013, read third time, passed. Yeas 77, nays 18.
February 25, 2013, read first time and referred to Committee on Health and Provider Services.
March 12, 2013, amended, reported favorably _ Do Pass.
PRINTING CODE. Amendments: Whenever an existing statute (or a section of the Indiana Constitution) is being amended, the text of the existing provision will appear in this style type, additions will appear in this style type, and deletions will appear in
Additions: Whenever a new statutory provision is being enacted (or a new constitutional provision adopted), the text of the new provision will appear in this style type. Also, the word NEW will appear in that style type in the introductory clause of each SECTION that adds a new provision to the Indiana Code or the Indiana Constitution.
Conflict reconciliation: Text in a statute in this style type or
A BILL FOR AN ACT to amend the Indiana Code concerning
health.
IC 16-42-19-5.
(b) "Practitioner", for purposes of IC 16-41-14, has the meaning set
forth in IC 16-41-14-4.
(c) "Practitioner", for purposes of IC 16-42-21, has the meaning set
forth in IC 16-42-21-3.
(d) "Practitioner", for purposes of IC 16-42-22 and IC 16-42-25,
has the meaning set forth in IC 16-42-22-4.5.
(1) the practitioner must:
(A) sign on the line under which the words "May substitute" appear; or
(B) for an electronically transmitted prescription, electronically transmit the instruction "May substitute."; and
(2) the pharmacist must inform the customer of the substitution.
(b) This section does not authorize any substitution other than substitution of a generically equivalent drug product.
Chapter 25. Drugs: Biosimilar Biological Products
Sec. 1. As used in this chapter, "biological product" means:
(1) a virus;
(2) a therapeutic serum;
(3) a toxin;
(4) an antitoxin;
(5) a vaccine;
(6) blood;
(7) a blood component;
(8) a blood derivative;
(9) an allergenic product;
(10) a protein (except any chemically synthesized polypeptide);
(11) a product analogous to a product described in subdivisions (1) through (10);
(12) arsphenamine;
(13) an arsphenamine derivative; or
(14) any other trivalent organic arsenic compound;
applicable to the prevention, treatment, or cure of a disease or condition for human beings.
Sec. 2. As used in this chapter, "biosimilar" means a biological product that:
(1) has been licensed as a biosimilar product under 41 U.S.C. 262(k); and
(2) is highly similar to the reference product, with:
(A) no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency of the product; and
(B) only minor differences in clinically inactive components.
Sec. 3. As used in this chapter, "interchangeable" means a determination by the Federal Food and Drug Administration that a biosimilar product may be substituted for a reference biological product without the intervention of the health care provider that prescribed the biological product.
Sec. 4. A pharmacist may substitute a biosimilar product for a prescribed biological product if the following conditions are met:
(1) The biosimilar product has been determined by the federal Food and Drug Administration to be interchangeable with the prescribed biological product.
(2) The prescribing practitioner has:
(A) for a written prescription, signed on the line under which the words "May substitute." appear; or
(B) for an electronically transmitted prescription, electronically transmitted the instruction "May substitute.".
(3) The pharmacist has informed the customer of the substitution.
(4) The pharmacist notifies the prescribing practitioner, orally, in writing, or electronically, within five (5) calendar days of the substitution.
(5) The pharmacy and the prescribing practitioner retain a written or electronic record of the interchangeable biosimilar substitution for at least five (5) years.
Sec. 5. (a) The Indiana board of pharmacy shall maintain a public Internet web site that contains a current list of biosimilar biological products that the federal Food and Drug Administration has determined to be interchangeable.
(b) The Indiana board of pharmacy may adopt rules under
IC 4-22-2 necessary to implement this chapter.
Sec. 6. A written or electronic prescription for a biological
product must comply with the requirements under IC 16-42-22-6.
(b) During the 2013 legislative interim, the commission shall study how Indiana law should address the prescribing and substituting of biosimilar biological products for other drugs.
(c) This SECTION expires December 31, 2013.
